QLT ends study of olopatadine punctal plugs

QLT’s (NSADAQ:QLTI; TSX:QLT) Phase 2 proof-of-concept clinical trial for the olopatadine punctal plug delivery system (O-PPDS) demonstrated that there were no significant differences between O-PPDS and placebo-PPDS subjects “with respect to reduction in the signs and symptoms of allergic conjunctivitis,” with both cohorts showing similar improvements. Internal study controls, including the olopatadine and placebo eye drop [...]

QLT to co-promote Activis PDT lasers

QLT Ophthalmics, a U.S. unit of QLT (TSX:QLT;NASDAQ:QLTI) and Quantel Medical have entered into a co-promotion agreement for the sale of Activis PDT lasers used to activate QLT’s Visudyne drug during photodynamic therapy of primarily classic lesions in wet age-related macular degeneration. The lasers are manufactured and sold by Quantel and will be promoted by [...]

QLT hikes size of share buyback

The board of QLT approved an increase in the number of common shares the company (TSX:QLT; NASDAQ:QLTI) may purchase under its normal course issuer bid to 4,700,060, or 10% of the public float, from  2,731,534, or 5% of the outstanding stock on Oct. 28, 2009. The 12-month buyback program ends on Nov. 2, 2010.  The [...]